Table of Contents — November 11, 2003, 61 (9 suppl 5) | Neurology

November 11, 2003; 61 (9 suppl 5)

Introduction

Anti-IFNβ antibodies in IFNβ-treated MS patientsSummary
Andrew R. Pachner
Full Text

Section I: Immunity to interferons and other biologicals

Anti-IFN BAb and NAb antibodiesA minireview
Klaus Bendtzen
Full Text
The immunogenicity of biopharmaceuticals
Huub Schellekens
Full Text
Strategies to treat and prevent the development of neutralizing anti-interferon-β antibodies
Gavin Giovannoni
Abstract

Full Text

Section II: Assays of antibodies to IFN\|[bgr ]\|

The measurement of antibodies binding to IFNβ in MS patients treated with IFNβ
Andrew R. Pachner, Joel Oger, Jacqueline Palace
Full Text
Perspectives on the neutralization of interferons by antibody
Sidney E. Grossberg
Abstract

Full Text

Section III: MxA assays as measurements of IFN

Measurement of MxA mRNA or protein as a biomarker of IFNβ bioactivityDetection of antibody-mediated decreased bioactivity (ADB)
Andrew R. Pachner, Antonio Bertolotto, Florian Deisenhammer
Abstract

Full Text

Section IV: Experience of MS centers with anti-IFN\|[bgr ]\| antibodies

Antibodies to IFN-betaThe Danish National IFN-beta Project
Per Soelberg Sorensen
Full Text
Long-term evolution of anti-INFβ antibodies in IFNβ-treated MS patientsThe London, Canada, MS Clinic experience
Marcelo Kremenchutzky
Full Text
Biologic impact of interferon antibodies, and complexities in assessing their clinical significance
Richard A. Rudick
Abstract

Full Text
Statistical approaches to assessing the effects of neutralizing antibodiesIFNβ-1b in the pivotal trial of relapsing-remitting multiple sclerosis
A. John Petkau
Abstract

Full Text
Statistical issues in neutralizing antibodies
Gary Cutter
Full Text